Top

Published in:

Open Access 01-12-2019 | Nosocomial Pneumonia | Study protocol

Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial

Authors: Dong Deng, Zhenyi Chen, Liyang Jia, Jianhong Bu, Miaoqing Ye, Lihua Sun, Yun Gen, Wen Zhang, Gang Chen, Bangjiang Fang

Published in: Trials | Issue 1/2019

Abstract

Background

Drug resistance in China is becoming a more and more serious issue. Infection by drug-resistant bacteria has become a major disease that seriously threatens the health of Chinese people and affects national medical finance. Therefore, it is of great scientific and clinical significance to actively carry out research on the prevention and treatment of infections by multi-drug resistant organisms (MDRO). Previous studies by the authors suggested that patients with hospital-acquired pneumonia caused by MDRO mostly showed the pathological state of “insufficient healthy Qi and internal accumulation of pathogenic Qi” and “acute deficiency syndrome” mainly characterized by Qi deficiency. Buzhong Yiqi decoction is a famous classic prescription in traditional Chinese medicine (TCM) for treating internal damage fever. This study intends to provide an evidence-based rationale for Buzhong Yiqi decoction in treating MDRO hospital-acquired pneumonia by conducting a multi-center randomized controlled clinical study.

Methods/design

This study is designed to be a multi-center randomized controlled study in which patients are assigned randomly into control (standard therapy) and trial (standard therapy plus Buzhong Yiqi decoction) groups. The patients will be selected from the emergency department and the ICU inpatient department of five study sites and will all be diagnosed with MDRO hospital-acquired pneumonia and meet the inclusion criteria. Forty patients are to be enrolled in each study site, resulting in a total of 200 patients in the study. The treatment course is 28 days.

Discussion

In this study: (1) the theory of “acute Qi deficiency” in MDRO hospital-acquired pneumonia is put forward for the first time, and the basic theories of TCM are further improved; (2) a multi-center randomized controlled clinical study will be performed for the first time with Buzhong Yiqi decoction, the classic prescription for reinforcing healthy Qi and eliminating pathogenic Qi, providing a reliable evidence-based rationale for the treatment of MDRO pulmonary infection with TCM; (3) the clinical application and modern disease spectrum of Buzhong Yiqi decoction is expanded, and the scientific notion of “treating different diseases with the same method” is enriched further.

Trial registration

China Clinical Trial Registry, ChiCTR1900022429. Registered on April 11, 2019. http://www.chictr.org.cn/listbycreater.aspx.

Available only for authorised users

Xie J, Yang Y, Huang Y, et al. The current epidemiological landscape of ventilator-associated pneumonia in the intensive care unit: A multicenter prospective observational study in China. Clin Infect Dis. 2018;67(suppl_2):S153–61. https://doi.org/10.1093/cid/ciy692.CrossRefPubMed

Millot G, Voisin B, Loiez C, et al. The next generation of rapid point-of-care testing identification tools for ventilator-associated pneumonia. Ann Transl Med. 2017;5(22):451. https://doi.org/10.21037/atm.2017.11.05.CrossRefPubMedPubMedCentral

Fernández-Barat L, Ferrer M, De Rosa F, et al. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance. J Infect. 2017;74(2):142–52. https://doi.org/10.1016/j.jinf.2016.11.008.CrossRefPubMed

Delle Rose D, Pezzotti P, Fortunato E, et al. Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals. Eur J Clin Microbiol Infect Dis. 2016;35(9):1531–9. https://doi.org/10.1007/s10096-016-2694-9.CrossRefPubMed

Martischang R, Buetti N, Balmelli C, et al. Nation-wide survey of screening practices to detect carriers of multi-drug resistant organisms upon admission to Swiss healthcare institutions. Antimicrob Resist Infect Control. 2019;8(1):37. https://doi.org/10.1186/s13756-019-0479-5.CrossRefPubMedPubMedCentral

Gysin DV, Cookson B, Saenz H, et al. Variability in contact precautions to control the nosocomial spread of multi-drug resistant organisms in the endemic setting: a multinational cross-sectional survey. Antimicrob Resist Infect Control. 2018;7(1):81. https://doi.org/10.1186/s13756-018-0366-5.CrossRefPubMedPubMedCentral

Magira EE, Islam S, Niederman MS. Multi-drug resistant organism infections in a medical ICU: Association to clinical features and impact upon outcome. Med Intensiva. 2018;42(4):225–34. https://doi.org/10.1016/j.medin.2017.07.006.CrossRefPubMed

Laszkowska M, Terry M, Whittier S, et al. Tu1399 timing and risk factors for gastrointestinal acquisition of multi-drug resistant organisms in the intensive care unit. Gastroenterology. 2016;150(4):S894–5. https://doi.org/10.1016/S0016-5085(16)33024-4.CrossRef

BangJiang F, Jianhong B. Study of traditional Chinese medicine and western medicine on septic shock. J Pract Shock. 2017;1(1):16–20,23 http://www.syxkzz.net/CN/Y2017/V1/I1/16.

10.

Fang BJ, Sun LH, Bu JH, et al. The discussion of acute deficiency syndrome theory and its clinical application in emergency medicine (I). J Emerg Tradit Chinese Med. 2017;26(10):1724–6. https://doi.org/10.3969/j.issn.1004-745X.2017.10.010.CrossRef

11.

Fang BJ, Sun LH, Bu JH, et al. The discussion of acute deficiency syndrome theory and its clinical application in emergency medicine (II). J Emerg Tradit Chinese Med. 2017;26(11):1943–6. https://doi.org/10.3969/j.issn.1004-745X.2017.11.017.CrossRef

12.

Fang BJ, Sun LH, Bu JH, et al. The discussion of acute deficiency syndrome theory and its clinical application in emergency medicine (III). J Emerg Tradit Chinese Med. 2017;26(12):2116–7. https://doi.org/10.3969/j.issn.1004-745X.2017.12.013.CrossRef

13.

Jiang X, Chen G, Huang J, et al. Modified Buzhong Yiqi decoction for myasthenia gravis: A systematic review protocol. Medicine (Baltimore). 2018;97(50). https://doi.org/10.1097/MD.0000000000013677.

14.

Wang DJ. Clinical application of Buzhong Yiqi decoction. J Tradit Chinese Med. 2010;51(S2):88–9. https://doi.org/10.13288/j.11-2166/r.2010.s2.183.CrossRef

15.

Nawen L. Examples of treatment of Buzhong Yiqi decoction. J Tradit Chinese Med. 2008;(01):93. https://doi.org/10.13288/j.11-2166/r.2008.01.046.

16.

Zhang LP, Fu ZL, Zhang DB, et al. Effect of Buzhong Yiqi decoction on the body temperature of fever animals invaded by Qi deficiency. J Tradit Chinese Med. 1998;(04):236–8. 196. https://doi.org/10.13288/j.11-2166/r.1998.04.027.

17.

Chen H, Wang YH, Fang BJ, et al. Clinical study of Quyu Jiedu Yiqi decoction in the treatment of severe sepsis. Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai. 2008;22(2):30–1. https://doi.org/10.16306/j.1008-861x.2008.02.009.CrossRef

18.

Pan XM, Lin XF. Treatment of 31 cases of stroke complicated with hospital acquired pneumonia with Western medicine and Buzhong Yiqi decoction. J Fujian Univ Trad Chinese Med. 2013;23(5):61–2. https://doi.org/10.13261/j.cnki.jfutcm.002868.CrossRef

19.

Zhao P, Guo DF, Lu CC, et al. Fang Bangjiang's experience in treating exogenous fever. Shanghai J Traditional Chinese Med. 2015;49(7):25–7. https://doi.org/10.16305/j.1007-1334.2015.07.008.CrossRef

20.

Hu B, An HM, Shen KP. Pharmacological study of Buzhong Yiqi Decoction: a review. Zhong Xi Yi Jie He Xue Bao. 2008;6(7):752–5. https://doi.org/10.3736/jcim20080718.CrossRefPubMed

21.

Guo X, Mao P, Fu SG, et al. Investigation of compatibility influence on the immuno-pharmacological effects of Buzhong Yiqi decoction. Chinese J Exp Tradit Med Formulae. 1999;(01):32–5. https://doi.org/10.13422/j.cnki.syfjx.1999.01.012.

22.

Tang B, Wu MY. Advances in immunopharmacology of Buzhong Yiqi Decoction. Chinese Trad Patent Med. 1995;(01):42–3 https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFD9495&filename=ZCYA501.022&uid=WEEvREcwSlJHSldRa1FhdkJkVG5ha1RXNERDb1pMMW8vdVRRQkEyMy9CYz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&v=MTIwMjVoQVU0amg0T1g2VHJIMDNlYk9kUkx1ZVl1ZHVGeTdnV2c9PVB5N1NiN2E0SDgvTXJZMHFGNTRPZmdnNXo=.

23.

Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287–91. https://doi.org/10.1002/pst.185.CrossRef

24.

Xu A, Zheng B, Xu YC, et al. National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. Clin Microbiol Infect. 2016;22 Suppl 1:S1–8. https://doi.org/10.1016/j.cmi.2015.09.015.CrossRefPubMed

25.

Boyle DP, Zembower TR. Epidemiology and management of emerging drug-resistant gram-negative bacteria: extended-spectrum β-lactamases and beyond. Urol Clin North Am. 2015;42(4):493–505. https://doi.org/10.1016/j.ucl.2015.05.005.CrossRefPubMed

26.

Lynch BL, Schaffer K. Can guidelines for the control of multi-drug resistant gram negative organisms be put into practice? A national survey of guideline compliance and comparison of available guidelines. J Hosp Infect. 2019:1–7. https://doi.org/10.1016/j.jhin.2018.12.017.

27.

Chellapandi K, Dutta TK, Sharma I, et al. Prevalence of multi drug resistant enteropathogenic and enteroinvasive Escherichia coli isolated from children with and without diarrhea in Northeast Indian population. Ann Clin Microbiol Antimicrob. 2017;16(1):49. https://doi.org/10.1186/s12941-017-0225-x.CrossRefPubMedPubMedCentral

28.

Rubio-Perez I, Martin-Perez E, Domingo-García D, et al. Specific clinical profile and risk factors for mortality in general surgery patients with infections by multi-drug-resistant Gram-negative bacteria. Surg Infect. 2017;18(5):625–33. https://doi.org/10.1089/sur.2016.255.CrossRef

Title: Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial
Authors: Dong Deng
Zhenyi Chen
Liyang Jia
Jianhong Bu
Miaoqing Ye
Lihua Sun
Yun Gen
Wen Zhang
Gang Chen
Bangjiang Fang
Publication date: 01-12-2019
Publisher: BioMed Central
Keyword: Nosocomial Pneumonia
Published in: Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-019-3927-x

At a glance: The STEP trials

Springer Medicine

Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial

Abstract

Background

Methods/design

Discussion

Trial registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods/design

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2019

Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience (EMPOWER) among Surrogate Decision-Makers of ICU Patients: study protocol for a randomized controlled trial

Effectiveness of an online self-management tool, OPERAS (an On-demand Program to EmpoweR Active Self-management), for people with rheumatoid arthritis: a research protocol

Comparison of dexmedetomidine vs. remifentanil combined with sevoflurane during radiofrequency ablation of hepatocellular carcinoma: a randomized controlled trial

Safety and efficacy of curcumin versus diclofenac in knee osteoarthritis: a randomized open-label parallel-arm study

Correction to: Contributions of Vitamin D in the management of depressive symptoms and cardiovascular risk factors: study protocol for a randomized, double-blind, placebo-controlled clinical trial

An analysis of deficiencies in the data of interventional drug trials registered with Clinical Trials Registry - India